Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for a leadership update with Bobbi Pritt, M.D. This week, Dr. Morice and Dr. Pritt talk about the importance of collaboration between laboratory professionals and other members of the patient care team, and they discuss the crucial role lab medicine plays in the clinical practice.

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for a leadership update with Bobbi Pritt, M.D. This week, Dr. Morice and Dr. Pritt discuss government regulation and oversight of lab developed tests, and review proposed legislation that would affect clinical laboratories.

Andrew McKeon, M.B., B.Ch., M.D., an expert in neuroimmunology, joins the "Answers From the Lab" podcast for a conversation with Bobbi Pritt, M.D. In this episode, Dr. McKeon and Dr. Pritt discuss how Mayo Clinic is pioneering advancements in the field of autoimmune neurology, how these discoveries were made, and why they are important to both patients and physicians.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt look at current trends in COVID-19 cases and hospitalizations, and they discuss advances in diagnosing the virus.

In this test specific episode of the  "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt explain what it means for a clinical laboratory to be licensed by CLIA (Clinical Laboratory Improvement Amendments), and discuss the important role of the lab director in a CLIA laboratory.

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate a malfunctioning metal hip implant. A Mayo Clinic study found that synovial fluid testing for those elements is more sensitive than serum or whole blood testing.

This week on "Answers From the Lab," William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt discuss how innovation in laboratories can address unmet patient needs and expand access to health care.

Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which have associations to thiopurine metabolization.

This week on "Answers From the Lab," William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt explain what lab developed tests are, why they are important, and how their quality is regulated.